Longeveron (LGVN) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free LGVN Stock Alerts $1.75 +0.08 (+4.79%) (As of 04:28 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLongeveron Inc. (NASDAQ:LGVN) Short Interest Updateamericanbankingnews.com - April 26 at 2:36 AMLongeveron to Present at the Planet MicroCap Showcaseglobenewswire.com - April 25 at 4:05 PMLongeveron secures $11.4 million from warrant exercisesinvesting.com - April 20 at 1:09 PMLongeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offeringglobenewswire.com - April 18 at 4:05 PMLongeveron Announces Exercise of Warrants for $6.2 Million Gross Proceedsglobenewswire.com - April 17 at 8:00 AMLongeveron stock rallies 85% on Alzheimer's presentation (update)msn.com - April 15 at 1:38 PMWhat's Going On With Longeveron Stock?msn.com - April 15 at 1:38 PMWhy Is Longeveron (LGVN) Stock Up 48% Today?markets.businessinsider.com - April 15 at 8:38 AMLongeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)finance.yahoo.com - April 15 at 8:38 AMLongeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)globenewswire.com - April 15 at 8:30 AMWhy Is Longeveron (LGVN) Stock Up 48% Today?investorplace.com - April 15 at 8:24 AMChief Scientific Officer Joshua Hare Acquires 148,936 Shares of Longeveron Inc (LGVN)finance.yahoo.com - April 13 at 8:35 AMMohamed Wa'el Ahmed Hashad Acquires 10,638 Shares of Longeveron Inc. (NASDAQ:LGVN) Stockinsidertrades.com - April 13 at 7:22 AMLongeveron Announces Closing of $5.2 Million Public Offeringglobenewswire.com - April 11 at 5:17 PMLongeveron Announces Pricing of $5.25 Million Public Offeringglobenewswire.com - April 8 at 2:15 PMLongeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goalsglobenewswire.com - April 8 at 8:30 AMWhy Is Longeveron (LGVN) Stock Up 82% Today?investorplace.com - April 8 at 7:56 AMLongeveron Inc. (NASDAQ:LGVN) Sees Large Decline in Short Interestmarketbeat.com - March 27 at 10:35 PMmarketbeat.com - March 27 at 6:06 AMLongeveron Announces 1-for-10 Reverse Stock Splitglobenewswire.com - March 19 at 4:01 PMLongeveron Full Year 2023 Earnings: EPS Misses Expectationsfinance.yahoo.com - March 1 at 7:40 AMLongeveron Inc. (LGVN) Q4 2023 Earnings Call Transcriptseekingalpha.com - February 29 at 4:23 PMLongeveron LLC earnings missed by $0.81, revenue topped estimatesinvesting.com - February 29 at 4:23 PMLongeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 28 at 10:14 AMRecap: Longeveron Q4 Earningsbenzinga.com - February 27 at 6:56 PMLongeveron Reports Year-End 2023 Results and Provides Corporate Updateglobenewswire.com - February 27 at 4:05 PMLongeveron Stock (NASDAQ:LGVN) Dividends: History, Yield and Datesbenzinga.com - February 22 at 6:38 AMLongeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024finance.yahoo.com - February 21 at 5:44 PMLongeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024globenewswire.com - February 21 at 4:05 PMBuy Rating Affirmed: Longeveron’s Intellectual Property and Pipeline Progress Signal Market Growthmarkets.businessinsider.com - January 30 at 11:46 AMLongeveron (NASDAQ: LGVN) Granted US Patent Allowance for Key Tech Behind Lead Investigation Producttheglobeandmail.com - January 30 at 11:46 AMLongeveron Shares Hit 52-Week Low After Direct Offering Pricesmarketwatch.com - December 21 at 1:17 PMWhy Longeveron (LGVN) Shares Are Falling Sharplymsn.com - December 21 at 1:17 PMUPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - December 21 at 1:17 PMLongeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - December 21 at 8:16 AMHC Wainwright & Co. Initiates Coverage of Longeveron Inc - (LGVN) with Buy Recommendationmsn.com - December 4 at 5:35 PMLong-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Associationbenzinga.com - November 11 at 9:59 AMLongeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 11 at 9:59 AMLong-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Associationfinance.yahoo.com - November 11 at 9:59 AMLGVN Continues to Show Progressmsn.com - November 10 at 1:52 PMLongeveron Reports Third Quarter 2023 Results and Provides Corporate Updatefinance.yahoo.com - November 10 at 8:52 AMLongeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023finance.yahoo.com - November 3 at 10:42 AMLongeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’sfinance.yahoo.com - October 24 at 8:48 AMNearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?benzinga.com - October 23 at 12:21 PMLongeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - October 12 at 9:32 AMLGVN Announces Positive Alzheimer’s Test Resultsfinance.yahoo.com - October 5 at 7:18 PMLongeveron Announces Positive Top-Line Results For Lomecel-BTM In Its CLEAR MIND Phase 2a Clinical Trial In The Treatment Of Mild Alzheimer's Diseasebenzinga.com - October 5 at 2:18 PMLongeveron: Phase 2a Trial Validate Safety, Therapeutic Potential Of Lomecel-B In Mild Alzheimer'smarkets.businessinsider.com - October 5 at 9:17 AMLongeveron stock jumps on Alzheimer’s trial resultsmsn.com - October 5 at 9:17 AMLongeveron (NASDAQ: LGVN) to Discuss Cellular Therapy Programs at H.C. Wainwright Conferencetheglobeandmail.com - September 15 at 9:35 AM Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. LGVN Media Mentions By Week LGVN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGVN News Sentiment▼0.150.32▲Average Medical News Sentiment LGVN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGVN Articles This Week▼41▲LGVN Articles Average Week Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCSA News CPHI News SEEL News XCUR News PTPI News THAR News NEXI News GNPX News CING News LIPO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGVN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
